Voyager Therapeutics (NASDAQ:VYGR) Now Covered by Analysts at Leerink Partners

Leerink Partners started coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report sent to investors on Wednesday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $15.00 target price on the stock.

Several other research firms have also issued reports on VYGR. StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, October 11th. Wedbush dropped their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Tuesday, August 20th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Voyager Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $17.43.

Voyager Therapeutics Price Performance

VYGR stock opened at $7.91 on Wednesday. Voyager Therapeutics has a 52-week low of $5.71 and a 52-week high of $11.72. The company has a 50-day moving average of $6.48 and a two-hundred day moving average of $7.73. The stock has a market capitalization of $430.26 million, a price-to-earnings ratio of -158.20 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. The company had revenue of $29.58 million during the quarter, compared to analysts’ expectations of $11.52 million. During the same period in the prior year, the company earned ($0.51) earnings per share. Equities analysts expect that Voyager Therapeutics will post -1.44 EPS for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. boosted its stake in Voyager Therapeutics by 49.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after purchasing an additional 1,300 shares during the period. Plato Investment Management Ltd acquired a new position in Voyager Therapeutics in the 1st quarter valued at $38,000. SG Americas Securities LLC bought a new position in shares of Voyager Therapeutics in the second quarter worth $85,000. ProShare Advisors LLC bought a new position in Voyager Therapeutics in the 1st quarter valued at about $101,000. Finally, Virtus Investment Advisers Inc. acquired a new position in Voyager Therapeutics during the first quarter valued at approximately $118,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.